Moderna to pay up to $2.25B to resolve patent lawsuit over Covid-19 vaccine technology

Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to its lipid nanoparticle technology for the delivery of mRNA in infectious disease vaccines. If Moderna pays full financial compensation to the companies, it would be one of the largest disclosed patent settlements in the history of the biopharmaceutical industry.

The post Moderna to pay up to $2.25B to settle patent lawsuit over Covid-19 vaccine technology appeared first on MedCity News.